Home›Trial›NCT05957276
NCT05957276Completed

Global Patient Registry of Inherited Retinal Diseases

Study Summary

The purpose of this study is to better understand the natural history of Inherited Retinal Disease (IRD) and help inform patient management.

Conditions
Inherited Retinal Diseases
Interventions / Drugs
Standard of Care
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C51/100
Study Details
Enrollment886 participants
Primary Completion2026-07-02
Lead SponsorJanssen Research & Development, LLC
Data Retrieved2026-10-14
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.

Primary completion: 2026-07-02
Enrolled: 886 participants
Sponsor Catalyst Profile

Johnson & Johnson (JNJ) is the sponsoring company for this trial. BiotechSign currently grades this company C (51/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

JNJ Full Pipeline →All Companies →
Other Trials from Johnson & Johnson
NCT05714202A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intrav…(PHASE3)NCT05923073A Study of Guselkumab in Pediatric Participants With Moderately to Severely Acti…(PHASE3)NCT04487080A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in …(PHASE3)NCT03431350A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castr…(PHASE2)NCT04919512A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Partic…(PHASE2)
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence